AU2019404339A1 - Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor - Google Patents

Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor Download PDF

Info

Publication number
AU2019404339A1
AU2019404339A1 AU2019404339A AU2019404339A AU2019404339A1 AU 2019404339 A1 AU2019404339 A1 AU 2019404339A1 AU 2019404339 A AU2019404339 A AU 2019404339A AU 2019404339 A AU2019404339 A AU 2019404339A AU 2019404339 A1 AU2019404339 A1 AU 2019404339A1
Authority
AU
Australia
Prior art keywords
cancer
certain embodiments
administered
benzylthio
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019404339A
Other languages
English (en)
Inventor
Paul Bingham
Sanjeev LUTHER
Timothy S. PARDEE
Robert G.L. Shorr
Shawn D. STUART
Zuzana Zachar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornerstone Pharmaceuticals Inc
Original Assignee
Rafael Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rafael Pharmaceuticals Inc filed Critical Rafael Pharmaceuticals Inc
Publication of AU2019404339A1 publication Critical patent/AU2019404339A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019404339A 2018-12-20 2019-12-20 Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor Abandoned AU2019404339A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862782928P 2018-12-20 2018-12-20
US62/782,928 2018-12-20
US201962793667P 2019-01-17 2019-01-17
US62/793,667 2019-01-17
US201962834475P 2019-04-16 2019-04-16
US62/834,475 2019-04-16
US201962854599P 2019-05-30 2019-05-30
US62/854,599 2019-05-30
PCT/US2019/067759 WO2020132397A1 (en) 2018-12-20 2019-12-20 Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor

Publications (1)

Publication Number Publication Date
AU2019404339A1 true AU2019404339A1 (en) 2021-06-24

Family

ID=71101607

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019404339A Abandoned AU2019404339A1 (en) 2018-12-20 2019-12-20 Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor

Country Status (8)

Country Link
EP (1) EP3897607A4 (zh)
JP (1) JP2022515171A (zh)
KR (1) KR20210105923A (zh)
CN (1) CN113543778A (zh)
AU (1) AU2019404339A1 (zh)
CA (1) CA3121929A1 (zh)
TW (1) TW202038931A (zh)
WO (1) WO2020132397A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023070101A1 (en) * 2021-10-22 2023-04-27 Cornerstone Pharmaceuticals, Inc. Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040882A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors

Also Published As

Publication number Publication date
KR20210105923A (ko) 2021-08-27
EP3897607A4 (en) 2022-08-24
CN113543778A (zh) 2021-10-22
WO2020132397A1 (en) 2020-06-25
TW202038931A (zh) 2020-11-01
CA3121929A1 (en) 2020-06-25
JP2022515171A (ja) 2022-02-17
EP3897607A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
US20220054445A1 (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor
TWI626061B (zh) 治療癌症之奈米粒子及其用途
TWI760306B (zh) 供治療癌症之口服投予紫杉醇及Ｐ-ｇｐ抑制劑的治療性組合
TWI557128B (zh) 組成物在製備用於預防或治療非小細胞肺癌之藥物之用途
AU2019404339A1 (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor
US11622950B2 (en) Therapeutic methods and compositions for treating pancreatic cancer using 6,8-bis-benzylthio-octanoic acid
JP2021521222A (ja) ６，８−ビス−ベンジルチオ−オクタン酸を使用して前立腺癌を治療するための治療方法および組成物
AU2009220942B2 (en) Methods of treatment employing prolonged continuous infusion of Belinostat
US20220040133A1 (en) Oral therapy using 6,8-bis-benzylthio-octanoic acid
US20150110864A1 (en) Novel antitumor agent comprising combination of three agents
US20210386736A1 (en) Combination therapy for treating cancer
US20220331279A1 (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and a glutaminase inhibitor
TWI815933B (zh) 包含6,8-雙-苄硫基-辛酸或其藥學上可接受的鹽的第一治療劑在製備治療胰臟癌之藥物上的用途
JPWO2015152407A1 (ja) 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤
WO2021224381A1 (en) Combination therapy for treating cancer
CN113631166A (zh) 用于治疗癌症的口服给药的伊立替康和P-gp抑制剂的治疗组合
CN115444938A (zh) cGAS抑制剂与化疗药物联合在制备治疗肺癌药物中的用途
CN114191557A (zh) Cdk4/6抑制剂联合免疫治疗在制备抗癌药物中的用途
CN107349203A (zh) 拉替拉韦减轻伊立替康毒性的医药新用途

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period